Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDARAVONE vs Fluoxetine-Safety-Postpartum
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Edaravone is a free radical scavenger that reduces oxidative stress by trapping hydroxyl radicals, peroxynitrite, and other reactive oxygen species, thereby protecting neuronal cells from oxidative damage.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
Treatment of amyotrophic lateral sclerosis (ALS)
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder,Premenstrual dysphoric disorder (off-label),Bipolar depression (off-label),Social anxiety disorder (off-label)
60 mg intravenously over 60 minutes once daily for 14 days, followed by a 14-day drug-free period, then 60 mg intravenously over 60 minutes once daily for 14 days.
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
Terminal elimination half-life is 4.5-6 hours. In patients with moderate hepatic impairment, half-life may be prolonged up to 9 hours. No significant accumulation with twice-daily dosing.
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
Edaravone is metabolized primarily via glucuronidation by UGT1A6, UGT1A9, and UGT2B7, and also undergoes sulfation. It is not significantly metabolized by CYP450 enzymes.
Hepatic via CYP2D6, CYP2C9, CYP3A4; active metabolite norfluoxetine.
Primarily renal excretion as unchanged drug and metabolites (approximately 60-70% unchanged edaravone in urine). Minor fecal elimination (<10%).
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
Approximately 90-92% bound to plasma proteins, primarily to albumin.
94% bound to albumin and alpha-1-acid glycoprotein
Volume of distribution is approximately 0.2-0.3 L/kg, indicating limited extravascular distribution. Predominantly distributes in extracellular fluid.
12-43 L/kg; extensive tissue distribution including brain, breast milk.
Oral bioavailability is approximately 50-60% due to first-pass metabolism. For the intravenous formulation (approved), bioavailability is 100% by definition.
Oral: 95% (72% after first-pass); food may slightly decrease rate but not extent.
No dose adjustment required for GFR ≥30 m L/min/1.73 m². Safety and efficacy not established for GFR <30 m L/min/1.73 m²; use with caution.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min), use cautiously with a maximum dose of 40 mg/day.
No specific guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment due to lack of data.
Child-Pugh Class A: 20 mg every other day; Class B: 20 mg every third day; Class C: avoid use or use 10 mg every third day with careful monitoring.
Not approved for use in pediatric patients; safety and efficacy not established.
Children (8-12 years): 10-20 mg orally once daily; adolescents (13-17 years): 20 mg orally once daily. Maximum 60 mg/day. Weight-based: 0.5-1.0 mg/kg/day, titrate to maximum 1.5 mg/kg/day.
No specific dose adjustment required; pharmacokinetic studies show no significant differences in elderly patients. Monitor renal function as age-related decline may occur.
Initial dose 10 mg orally once daily; titrate slowly to a maximum of 40 mg/day due to increased half-life and risk of hyponatremia and QT prolongation.
None.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Hypersensitivity reactions (e.g., urticaria, dyspnea) have been reported; discontinue if severe.,Monitor for sulfite sensitivity in patients with asthma (contains sodium bisulfite).,Renal impairment: Not recommended in severe renal impairment (Cr Cl <30 m L/min).,Hepatic impairment: Use with caution in moderate to severe hepatic impairment.
Serotonin syndrome; risk of bleeding; activation of mania/hypomania; hyponatremia; discontinuation syndrome; QT prolongation (overdose).
Hypersensitivity to edaravone or any of its excipients.,Severe renal impairment (Cr Cl <30 m L/min).
Concurrent use with MAOIs (or within 14 days); concurrent use with thioridazine or pimozide; known hypersensitivity to fluoxetine.
No significant food interactions reported. No dietary restrictions known.
No specific food interactions; avoid grapefruit juice as it may increase fluoxetine levels. Take with or without food; if GI upset occurs, take with food.
Edaravone is not recommended during pregnancy due to lack of adequate human data. In animal studies, intravenous administration during organogenesis resulted in increased fetal malformations (e.g., skeletal abnormalities) at doses below the human equivalent. Risk cannot be excluded for all trimesters.
First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/third trimester: Persistent pulmonary hypertension of the newborn (PPHN) risk ~1.5-2 times baseline; risk of preterm birth and low birth weight. Late third trimester: Risk of poor neonatal adaptation syndrome (PNAS) including jitteriness, respiratory distress, feeding difficulties, and irritability.
No data on edaravone excretion in human milk. M/P ratio unknown. Due to potential for adverse effects in nursing infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk; M/P ratio ~0.3-1.0 for fluoxetine and ~0.5-2.0 for norfluoxetine. Relative infant dose approximately 2-12% of maternal weight-adjusted dose. Cases of colic, irritability, and poor feeding in breastfed infants have been reported. Generally considered compatible with breastfeeding; however, monitor infant for sedation, poor weight gain, and development.
No pharmacokinetic data in pregnancy; dose adjustments are not established. Use only if potential benefit justifies risk to fetus; consider alternative treatments if pregnancy occurs.
Pregnancy increases fluoxetine clearance and decreases plasma concentrations, especially in the third trimester. Dose may need to be increased by 20-50% (e.g., from 20 mg to 30-40 mg daily) to maintain therapeutic effect. Consider therapeutic drug monitoring if available. Postpartum, dose should be reduced to pre-pregnancy levels within 48-72 hours due to reversal of pharmacokinetic changes.
Monitor for hypersensitivity reactions, including anaphylaxis; edema and gait disturbance are common adverse effects. Avoid use in patients with severe hepatic impairment. Administer intravenous infusion over 60 minutes; do not mix with other medications in the same bag. Renal function monitoring recommended.
Fluoxetine has a long half-life (4-6 days, norfluoxetine 4-16 days) resulting in steady-state after 2-4 weeks; use lower starting doses (10 mg daily) in postpartum women to minimize side effects; monitor for neonatal adaptation syndrome if used in third trimester; consider dose adjustment in hepatic impairment; avoid in breastfeeding unless benefit outweighs risk due to presence in breast milk.
This medication is used to slow the progression of ALS symptoms.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately.,You may experience swelling in the legs or difficulty walking; notify your doctor if these become severe.,Do not drive or operate heavy machinery until you know how the medication affects you.,Keep all appointments for infusion and blood tests to monitor your kidney function.
Take fluoxetine exactly as prescribed, typically once daily in the morning.,It may take 4 weeks or longer to feel full benefit; do not stop abruptly.,Common side effects include nausea, headache, insomnia, and sexual dysfunction.,Contact your doctor if you experience rash, unusual bleeding, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not breastfeed without discussing risks with your healthcare provider.
No interactions on record
"Pazopanib, a tyrosine kinase inhibitor, inhibits CYP2D6 activity, leading to reduced metabolism of fluoxetine, a substrate of CYP2D6. This results in increased serum concentrations of fluoxetine and its active metabolite norfluoxetine, elevating the risk of serotonin-related adverse effects such as serotonin syndrome, nausea, and insomnia. The interaction is clinically significant and may require dose adjustment of fluoxetine."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"Concomitant use of tolcapone, a catechol-O-methyltransferase (COMT) inhibitor used in Parkinson's disease, with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), may potentiate serotonergic effects leading to serotonin syndrome, characterized by autonomic instability, neuromuscular hyperactivity, and altered mental status. Additionally, both drugs undergo hepatic metabolism via CYP450 enzymes, and fluoxetine's inhibition of CYP2C9 and CYP3A4 may reduce tolcapone clearance, increasing the risk of hepatotoxicity and other adverse effects. The combination requires careful monitoring for signs of serotonin toxicity and liver injury."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDARAVONE vs Fluoxetine-Safety-Postpartum, answered by our medical review team.
EDARAVONE is a Amyotrophic Lateral Sclerosis Agent that works by Edaravone is a free radical scavenger that reduces oxidative stress by trapping hydroxyl radicals, peroxynitrite, and other reactive oxygen species, thereby protecting neuronal cells from oxidative damage.. Fluoxetine-Safety-Postpartum is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDARAVONE and Fluoxetine-Safety-Postpartum depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDARAVONE is: 60 mg intravenously over 60 minutes once daily for 14 days, followed by a 14-day drug-free period, then 60 mg intravenously over 60 minutes once daily for 14 days.. The standard adult dose of Fluoxetine-Safety-Postpartum is: 20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDARAVONE and Fluoxetine-Safety-Postpartum in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDARAVONE is classified as Category C. Edaravone is not recommended during pregnancy due to lack of adequate human data. In animal studies, intravenous administration during organogenesis resulted in increased fetal mal. Fluoxetine-Safety-Postpartum is classified as Category A/B. First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.